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BACKGROUND: Non-Hodgkin lymphoma (NHL) are a heterogeneous group of 
malignancies of the lymphoid system and represents approximately 80% of all lym-
phomas. Mortality associated with NHL in Brazil has increased in the last few years, 
from 2772 cases in 2000 to 3194 in 2004. Aggressive NHL accounts for approxi-
mately 60% of all cases and cure can be achieved in more than 70% of cases with 
rates ranging 50% to 90% when under immunochemotherapy depending on the clini-
cal stage and international prognostic index (IPI). Currently, only CHOP therapy is 
available to patients presenting with aggressive NHL in Brazilian Public Healthcare 
System. OBJECTIVES: To evaluate the epidemiological impact of adding rituximabe 
(R) to CHOP ﬁ rst-line therapy (cyclophosphamide, doxorubicin, vincristine, and 
prednisone) on the annual number of patients experiencing recurrence and deaths 
between 2010 and 2020 in Brazil. METHODS: Annual aggressive NHL incidence for 
2010 to 2020 was estimated by applying published age-speciﬁ c NHL incidence to 
Brazilian population projections for the mentioned period. Projections were made for 
aggressive NHL and population above 20-year-olds only. Therapy effect for R-CHOP 
and CHOP was derived from Gao (2009) and 2-year overall survival and disease 
control data were adjusted for a 1-year rate. Considering the subgroups analysis, 
annual overall survival rate were 54.5% and 45.7% and disease control rate were 
43.7% and 31.1% for R-CHOP and CHOP, respectively. RESULTS: Between 2010 
and 2020, it is estimated that 8886 more patients would be saved if R-CHOP was 
given (54,917 vs. 46,031 for CHOP). Regarding disease progression, R-CHOP has 
the potential to control the disease in 12,703 more patients than CHOP (44,048 vs. 
31,345). CONCLUSIONS: Findings suggest that R-CHOP has the potential to save 
about 16% more lives annually when compared to CHOP in the management of 
aggressive NHL, particularly in Brazilian patients who have late diagnosis which 
implies a worse prognosis.
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OBJECTIVES: Trastuzumab was approved for the treatment of HER2-positive early 
breast cancer (EBC) in 2006 in several European countries, Portugal included. The 
model assesses the impact of trastuzumab treatment in EBC on the annual number of 
patients entering the metastatic setting between 2005 and 2015 in Portugal. 
METHODS: Annual EBC incidence for 2005 to 2015 was projected by applying 
stage-speciﬁ c proportions for stages I–III to female breast cancer incidence rates esti-
mated for 2008 (GLOBOCAN 2010), using a conjoint estimate based on English 
cancer registries, where overall breast cancer survival is comparable to that seen in 
Portugal. Age-speciﬁ c rates were applied to UN population projections for 2000 to 
2025. The annual number of patients with HER2-positive metastatic breast cancer 
(MBC) includes de novo and recurrent MBC patients. The baseline 10-year recurrence 
rate was estimated as 37%, based on 4-year follow-up in the control arm of a com-
bined trial analysis in patients with HER2-positive breast cancer and the long-term 
timing of recurrence in all patients with breast cancer. To model recurrence in trastu-
zumab-treated EBC patients, the hazard ratio (HR) from the HERA trial (0.49; 95% 
CI: 0.38, 0.63) was applied. RESULTS: In 2004, prior to approval of trastuzumab in 
EBC, the pool of de novo and relapsed MBC patients was estimated to be 650. 
Between 2005 and 2015, the model predicts that the use of trastuzumab will result in 
an average annual decline in recurrence of MBC of 5.2% (95% CI: 3.0, 6.7). Cumula-
tive recurrence prevented by trastuzumab treatment between 2005 and 2014 (pro-
jected through full 10-year window for recurrence) is projected to be 884 (95% CI: 
537; 1075). CONCLUSIONS: Trastuzumab treatment of HER2-positive EBC over a 
10-year period is expected to prevent nearly 900 women from developing metastases 
in Portugal, which may result in a similar number of breast cancer deaths being 
avoided.
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OBJECTIVES: To investigate prescription patterns for setron antiemetics used along-
side chemotherapy in France, Germany, Italy, and the UK. METHODS: Prescription 
data from June 2008 to July 2009 were extracted from the Synovate Oncology 
Monitor, an ongoing database tracking prescriptions of anticancer therapies and 
concomitant medications. Patients receiving setron prophylaxis (dolasetron, granise-
tron, ondansetron, palonosetron, or tropisetron) with Moderately emetic chemo-
therapy (MEC) or highly emetic chemotherapy (HEC) were selected. RESULTS: The 
sample included 1715, 1658, 1830, and 1651 patients with MEC regimens in France, 
Germany, Italy, and UK, respectively, and 557, 761, 903, and 627 patients with HEC 
regimens. Ondansetron was used in 85.1%, 45.8%, 52.1%, and 83.3% of patients 
with MEC regimens in France, Germany, Italy, and UK respectively, and 92.5%, 
46.0%, 43.8%, and 62.2% of patients with HEC regimens. The shares of different 
setrons were relatively similar between MEC and HEC regimens in Gemany. a stronger 
association between setron and regimen category was found in other countries, with 
different trends according to country. Doses of setrons were slightly higher for HEC 
regimens than for MEC regimens in Italy, but substantially higher in other countries. 
The average daily dose was found to increase with treatment duration in all countries. 
Neurokinin 1 antagonists (NK1) were used alongside setron in up to 46% of patients 
in Germany, depending on setron, but were very rarely used in Italy. CONCLUSIONS: 
Utilization of setrons and concomitant medications (NK1, antipsychotics) varied 
widely between European countries. It appears that German prescribers adapted the 
dose of setron rather than the drug according to regimen category, contrary to Italian 
prescribers. Such international comparisons may provide useful insight for improving 
practice in different countries.
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OBJECTIVES: In South Korea, 2617 new cases of head and neck cancer (HNC) were 
diagnosed and 1473 deaths were reported in 2005. In Western countries, SCCHN 
represents more than 90% of HNCs and surgery is the primary treatment modality 
for SCCHN. Chemotherapy is often an important treatment component combined 
with radiotherapy for patients diagnosed with locally advanced disease. This study 
aimed to estimate the number of resected SCCHN patients and describe their treatment 
and health-care utilization in South Korea. METHODS: The study included the fol-
lowing cancer sites: oral cavity, pharynx, and larynx. The main source of data for the 
probabilities of having different types of SCCHN treatments was results from retro-
spective analyses found through literature review using MEDLINE, EMBASE, 
Cochrane, and the Korean Medical Database. Cancer incidence was based on data 
from the National Cancer Registry. In addition, expert opinion of a HNC surgeon in 
South Korea complemented the literature review. RESULTS: We estimated that 
SCCHN constituted 91% of HNC cases; 69% of the SCCHN cases were surgically 
resected. The number of new cases of resected SCCHN in South Korea was 1642 (oral 
cavity, 501; pharynx, 397; and larynx, 744). Fiﬁ ty-two percent of resected SCCHN 
patients had neck dissections (45% of them were radical neck dissections) and 6% of 
resected SCCHN patients had total laryngectomy. Ten percent of patients had second-
ary surgery and 75% had reconstructive surgery. Sixty-four percent of patients 
received radiotherapy, whereas 33% received chemotherapy combined with surgery 
or as concomitant therapy with radiotherapy. CONCLUSIONS: In South Korea, 
resected SCCHN is estimated to constitute 1% of all cancers. However, 29% of 
patients with resected SCCHN had major surgeries (radical neck dissection or total 
laryngectomy), causing a signiﬁ cant negative impact on the quality of life of patients 
and contributing to a high economic burden to the patients and society.
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OBJECTIVES: ERCC1 mRNA expression has the potential to be a useful tool in the 
clinical treatment of advanced NSCLC; however, considerable uncertainty remains as 
to the biomarker’s magnitude of effect on tumor response and survival. The objective 
of this study was to evaluate the association between ERCC1 mRNA expression level 
and treatment outcomes in advanced NSCLC patients treated with platinum-based 
chemotherapy using a systematic review and meta-analytic techniques. METHODS: 
A systematic search of the literature was conducted using MEDLINE and EMBASE 
databases from June 1995 to May 2010. Additionally, a search of ASCO Annual 
Meeting abstracts was conducted. Eligible studies were evaluated for clinical, meth-
odological, and statistical heterogeneity. Pooled RESULTS: The pooled analysis dem-
onstrated a statistically signiﬁ cant higher probability of response (according to the 
RECIST criteria) to platinum-based chemotherapy for patients with low ERCC1 
mRNA expression levels relative to patients with high ERCC1 mRNA expression 
levels (OR: 0.64, 95% CI 0.42–0.95). Low ERCC1 mRNA expression level was also 
associated with signiﬁ cantly improved overall survival relative to high mRNA expres-
sion levels (HR: 0.44, 95% CI 0.31–0.62). CONCLUSIONS: In conclusion, ERCC1 
mRNA expression level may provide useful clinical information in terms of the likeli-
hood of platinum-based chemotherapy response and overall survival prognosis. 
Ongoing analyses are focused on evaluating the predictive role of ERCC1 in overall 
survival. The ﬁ ndings of this analysis also reveal a need for standardization in char-
acterizing “high” and “low” ERCC1 mRNA expression, as the studies evaluated 
herein varied considerably in their methods. 
